Changes for page Intercept Pharmaceuticals

Last modified by Asif Farooqui on 2019/11/12 11:01
From version < 1.2 >
edited by Asif Farooqui
on 2019/11/12 10:31
To version < 1.3 >
edited by Asif Farooqui
on 2019/11/12 10:32
< >
Change comment: There is no comment for this version

Summary

Details

Page properties
Content
... ... @@ -2,12 +2,10 @@
2 2  {{toc/}}
3 3  {{/box}}
4 4  
5 -= Paragraph 1 =
5 += Overview =
6 6  
7 -==== Overview ====
7 +Intercept Pharmaceuticals (ICPT) is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases with high unmet medical need utilizing its proprietary bile acid chemistry. The company's one marketed product, OCA, and portfolio of clinical product candidates have the potential to treat orphan and more prevalent liver diseases for which, currently, there are limited therapeutic solutions.
8 8  
9 -Intercept Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases with high unmet medical need utilizing its proprietary bile acid chemistry. The company's one marketed product, OCA, and portfolio of clinical product candidates have the potential to treat orphan and more prevalent liver diseases for which, currently, there are limited therapeutic solutions.
10 -
11 11  OCA was approved in the United States in May 2016 for use in patients with PBC, under the brand name Ocaliva® (obeticholic acid). OCA is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid, that selectively binds to and activates the farnesoid X receptor, or FXR. The company believe OCA has broad liver-protective properties and may effectively counter a variety of chronic insults to the liver that cause fibrosis, or scarring, which can eventually lead to cirrhosis, liver transplant and death. The company commenced sales and marketing of Ocaliva in the United States shortly after receiving such marketing approval, and Ocaliva is now available to patients primarily through a network of specialty pharmacy distributors. In December 2016, the European Commission granted conditional approval for Ocaliva for the treatment of PBC and the company commenced its European commercial launch in January 2017. Intercept Pharmaceuticals has submitted or are in the process of submitting dossiers to a number of reimbursement authorities in the European Union. In May 2017, Health Canada granted a conditional approval for Ocaliva in PBC and the company commenced its commercial launch in July 2017. The company also plan to file for marketing authorization for OCA in PBC in other target markets.
12 12  
13 13  Intercept Pharmaceuticals is currently evaluating its future development strategy for OCA in other indications, including a variety of other non-viral progressive liver diseases such as nonalcoholic steatohepatitis, or NASH, primary sclerosing cholangitis, or PSC, and biliary atresia.
This site is funded and maintained by Fintel.io